Cached score snapshot

US.EW · Edwards Lifesciences

110分制 49.7/110;5D動能v2 7/50;排序分 56.7/160

Ranking score 56.7/160
Main score 49.7/110
5D momentum v2 7/50
Rank #207
Setup grade F 26

Score breakdown

避免

Medium twelvedata

Score and price trend

F 26 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 07-01 09-24 10-09 10-23 11-05 $79.70$90.29$100.88 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.515 · anchors 120 +0.04% -1.53% / +3.04% 50% 5% Actual +2.74% · vs median +2.70% · inside 25-75 band
30D observation +5.41% +0.76% / +13.40% 77.5% 5% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +0.09% -1.60% / +2.56% 51.3% 2.5% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。

2026-07-01 → 2026-11-05 · 235 archived points · 1 Improving turn signal · 6 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 56.7
Display grade 避免
Model version cursor_18_27_news_v2_160
Main score 49.7/110 (避免)
5D momentum v2 7/50 (弱)
Score with momentum v2 56.7/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 88.1455
ma50 88.3498
close 85.73
prevClose 86.82
avgVolume20 3273756
volumeRatio 1.18
changePercent -1.26

Metrics snapshot

close 85.73
volume 3868915
changePercent -1.26

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 49.7/110
Main rating 避免
5D momentum v2 7/50
Score with momentum v2 56.7/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 2.7/5 · 較差

Dimension score 2.7/5
Dimension grade 較差

Sub-items

pbPoints 0.2
pePoints 0.2
epsPoints 0
roePoints 0
debtPoints 0.5
marginPoints 0.4
turnoverUsdM 331.6821
volumePoints 0.5
revenuePoints 0.4
dividendPoints 0
marketCapPoints 0.5

資金流 — 9.2/20 · 較差

Dimension score 9.2/20
Dimension grade 較差

Sub-items

cmfPoints 0.8
mfiPoints 1.6
obvPoints 4
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.EW
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 10.2/15 · 一般

Dimension score 10.2/15
Dimension grade 一般

Sub-items

vix

score 2.4

details

source twelvedata+fred
vixClose 14.21

trend

score 4

details

qqq

ma20 719.705
ma50 711.8824
name QQQ
close 741.1
points 2

spy

ma20 765.338
ma50 761.1532
name SPY
close 767.18
points 2
source twelvedata+fred
atrPct 2.5328
atrPoints 3
cciPoints 0.8
vixPoints 2.4
marketTrendPoints 4

催化劑 — 2/20 · 較差

Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 5
catalystCount 0
catalystPoints 2

風險管理 — 6.8/10 · 一般

Dimension score 6.8/10
Dimension grade 一般

Sub-items

position

score 1.6

details

atrPct 2.5328
turnoverUsdM 331.6821
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.EW
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 81.3872

strength_details

ma_score 1
atr_score 2
rsi_score 2.5
macd_score 1
volume_score 2
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 5.1
take_profit_price 90.2682
target_multiplier 1.9
technical_strength 1.65
take_profit_percent 5.3
positionPoints 1.6
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 5.0657
diversificationPoints 2

技術信號 — 14.8/30 · 較差

Dimension score 14.8/30
Dimension grade 較差

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 2.4
vcpPoints 1.7
macdPoints 0.8

vcpPayload

vcp_pass false
vcp_score 1.7
vcp_reason 波幅收縮(11.6%→6.9%);升放量(近10日5日);Ready=N;Confirm=N

vcp_metrics

up_days 6
vol_ref 3045843.2333
down_days 3
vcp_ready false
above_ma50 false
avg_vol_10 3652139.7
avg_vol_20 3219214.85
avg_vol_30 3045843.2333
range_pct_10 0.0687
range_pct_20 0.1066
range_pct_30 0.1159
up_expand_ok true
lookback_used 59
near_20d_high false
contraction_ok true
down_shrink_ok false
up_expand_days 5
breakout_20d_ok false
vol_ratio_10_30 1.1991
dist_to_20d_high 0.0777
down_shrink_days 0
breakout_level_20d 92.95
vcp_breakout_confirm false
contraction_ratio_10_30 0.5926
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction true
kdjAdxPoints 0.5
rsiKdjPoints 1.6
volumeWeight 2
maCrossPoints 0.8
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 0
volumePointsTechnical 1.2

情緒分析 — 4/10 · 較差

Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 5
negativeHits 0
positiveHits 2
sentimentScoreRaw 1

sentimentData

raw {"id":142266550,"url":"https://finnhub.io/api/news?id=da0f8c9693d571ce918d448e54f2a4e1f344477545ea3925d87467465be4b61c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences recently outlined its structural heart growth plan, emphasizing transcatheter valve platforms such as TAVR and TMTT, alongside the impact of updated Medicare coverage that could enable 100–200 additional U.S. centers to perform TAVR procedures. A particularly important takeaway is Edwards’ ambition to build a multibillion-dollar transcatheter mitral and tricuspid business by 2030, anchored by PASCAL, EVOQUE, and Sapien M3 technologies that aim to address complex...","category":"company","datetime":1789769713,"headline":"How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions"}, {"id":142260140,"url":"https://finnhub.io/api/news?id=e456714e92954de98b33d6053fadb104ecebefa6f418a514898827cc6f127659","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences has delivered a mixed share price story, with the stock up 18.4% over the past year but still down sharply over a 5 year span. This puts the focus squarely on what investors are paying for its future cash flows. With fresh policy news around its core heart valve franchise and a current share price of US$88.25, the key issue is whether the company’s cash generation can support where the stock trades today. Over 5 years the share price has declined 27.1%, which raises the...","category":"company","datetime":1789755142,"headline":"Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion"}, {"id":142197743,"url":"https://finnhub.io/api/news?id=9b56623bc1072bd0de84cf62140ea790418711ad90edb1c273a8b5b42899b3ea","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"EW","summary":"Edwards Lifesciences Corporation (EW) Deutsche Bank 2026 Healthcare Summit September 16, 2026 10:00 AM EDTCompany ParticipantsBernard Zovighian - CEO &...","category":"company","datetime":1789563698,"headline":"Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript"}, {"id":141363799,"url":"https://finnhub.io/api/news?id=333be4e944228107f46e82eb4c189a5712c79cf2a54bcdd91358dfdbbae466ef","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"An unusually high volume of out-of-the-money (OTM) put options in Edwards Lifesciences (EW) shows investors are bullish on EW stock over the next three months. Moreover, EW is below analysts' price targets.","category":"company","datetime":1788201002,"headline":"Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock"}, {"id":141363800,"url":"https://finnhub.io/api/news?id=132ff0d47621e88db46c1e729e50927f8e2bf5baad2df7f08e374cd83482bbe8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]","category":"company","datetime":1787938897,"headline":"Edwards Lifesciences (EW): The Medical Device Leader Behind the TAVR Boom"}
raw_source {"id":142266550,"url":"https://finnhub.io/api/news?id=da0f8c9693d571ce918d448e54f2a4e1f344477545ea3925d87467465be4b61c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences recently outlined its structural heart growth plan, emphasizing transcatheter valve platforms such as TAVR and TMTT, alongside the impact of updated Medicare coverage that could enable 100–200 additional U.S. centers to perform TAVR procedures. A particularly important takeaway is Edwards’ ambition to build a multibillion-dollar transcatheter mitral and tricuspid business by 2030, anchored by PASCAL, EVOQUE, and Sapien M3 technologies that aim to address complex...","category":"company","datetime":1789769713,"headline":"How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions"}, {"id":142260140,"url":"https://finnhub.io/api/news?id=e456714e92954de98b33d6053fadb104ecebefa6f418a514898827cc6f127659","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences has delivered a mixed share price story, with the stock up 18.4% over the past year but still down sharply over a 5 year span. This puts the focus squarely on what investors are paying for its future cash flows. With fresh policy news around its core heart valve franchise and a current share price of US$88.25, the key issue is whether the company’s cash generation can support where the stock trades today. Over 5 years the share price has declined 27.1%, which raises the...","category":"company","datetime":1789755142,"headline":"Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion"}, {"id":142251945,"url":"https://finnhub.io/api/news?id=37512db8dc48a1b609e465c892d8209fa7791765c124efa21b1a41a2ce7135c3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"The global interventional cardiology devices market is forecast to grow from USD 31.12 billion in 2026 to USD 42.39 billion by 2031, at a 6.4% CAGR. Growth is driven by rising cardiovascular disease, aging populations, demand for minimally invasive procedures, better healthcare access, and advances in stents, imaging and catheter technologies. Plain angioplasty balloons, embolic protection devices, guidewires and hospitals will see strong growth, while Asia Pacific is set to be the fastest-growi","category":"company","datetime":1789727580,"headline":"Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031"}, {"id":142225420,"url":"https://finnhub.io/api/news?id=3f481a7df661c8f98de5df77adb029ad06c1cffb737eba375692d975ae4fc193","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Edwards Lifesciences (NYSE:EW) outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE","category":"company","datetime":1789642943,"headline":"Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead"}, {"id":142198959,"url":"https://finnhub.io/api/news?id=568783958075196b65740530debea12cb32f6534984a1b55719ef4f7c7471b7c","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"EW","summary":"Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.","category":"company","datetime":1789585501,"headline":"Explore the top gainers and losers within the S&P500 index in today's session."}, {"id":142197673,"url":"https://finnhub.io/api/news?id=30298a7b867fc3d1c8506990163ac5c9a3e40dd91ed64cc86b4796e19106bb06","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"EW","summary":"Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Wednesday.","category":"company","datetime":1789576500,"headline":"What's going on in today's session: S&P500 movers"}, {"id":142197743,"url":"https://finnhub.io/api/news?id=9b56623bc1072bd0de84cf62140ea790418711ad90edb1c273a8b5b42899b3ea","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"EW","summary":"Edwards Lifesciences Corporation (EW) Deutsche Bank 2026 Healthcare Summit September 16, 2026 10:00 AM EDTCompany ParticipantsBernard Zovighian - CEO &...","category":"company","datetime":1789563698,"headline":"Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript"}, {"id":142163400,"url":"https://finnhub.io/api/news?id=712ca2141d14c09265822f1d9ad959df7e8bcf8783050923b13cc6f764bc4616","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536","source":"Benzinga","related":"EW","summary":"Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 7.57% on an annualized basis producing an average annual return of 16.73%. Currently, Edwards Lifesciences has a market capitalization","category":"company","datetime":1789410618,"headline":"$100 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth This Much Today"}, {"id":142089165,"url":"https://finnhub.io/api/news?id=730ee985635cf2cb4174a462055018cf2fb3f8c1a7fa9df3fbe6e9889f37215f","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"EW","summary":"Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.","category":"company","datetime":1789153501,"headline":"Top S&P500 movers in Friday's session"}, {"id":142087699,"url":"https://finnhub.io/api/news?id=d008f77c83c23655aa93afca754d58b5809bf8c51f25fceeb225e41d40e1da58","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"EW","summary":"Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session.","category":"company","datetime":1789144501,"headline":"Stay informed with the top movers within the S&P500 index on Friday."}, {"id":142088351,"url":"https://finnhub.io/api/news?id=5b13fc1b3e7da5df89780e934cc69daf787479d049e9ace50f6b66fc848fab41","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"The Centers for Medicare and Medicaid Services’ policy update extends Medicare coverage to severe aortic stenosis patients without symptoms, a change that analysts said will especially benefit Edwards Lifesciences.","category":"company","datetime":1789128882,"headline":"CMS expands TAVR Medicare coverage to asymptomatic patients"}, {"id":142087525,"url":"https://finnhub.io/api/news?id=e1db2e5e73f465a1830dd146275cae0b8f5ac8ba767db9834b8b45a100a239d4","image":"","source":"Benzinga","related":"EW","summary":"BTIG analyst Marie Thibault reiterates Edwards Lifesciences (NYSE:EW) with a Buy and maintains $110 price target.","category":"company","datetime":1789106253,"headline":"BTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target"}, {"id":142066287,"url":"https://finnhub.io/api/news?id=23a1bbb562bdd05c03a4889d81973e892c03106cf45f4948eabd82d8e4834812","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"IRVINE, Calif., September 10, 2026--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):","category":"company","datetime":1789076940,"headline":"Edwards Lifesciences Comments on TAVR National Coverage Decision"}, {"id":141951037,"url":"https://finnhub.io/api/news?id=da6fa2d576819e8545394b26df1efa3f372cede55f32e64c0297eaa73a0dda31","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Despite lagging behind the Dow over the past 12 months, Edwards Lifesciences continues to receive a highly bullish outlook from Wall Street analysts.","category":"company","datetime":1788859207,"headline":"Is Edwards Lifesciences Stock Underperforming the Dow?"}, {"id":141758077,"url":"https://finnhub.io/api/news?id=f0abeae7b345fcf63f4ae44fa3cce64a78b15eb65c0eec0d640baaff2b2fd7c4","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249179691/image_2249179691.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"EW","summary":"Baron Asset Fund initiated a position in Edwards Lifesciences due to its dominant heart valve market share. Read the full analysis for more details.","category":"company","datetime":1788750600,"headline":"Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound"}, {"id":141437930,"url":"https://finnhub.io/api/news?id=363996b5598cdc6cbd4a9ff5b8357ca4a6e2dfb3b9ccf4040974e9945cfc3d7f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","category":"company","datetime":1788535817,"headline":"Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?"}, {"id":141381180,"url":"https://finnhub.io/api/news?id=aff4cd1f434fbbb0d65c87f29c8c7560f83d23928031121fd5c2ed58c880051b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"IRVINE, Calif., September 02, 2026--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.","category":"company","datetime":1788383700,"headline":"Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit"}, {"id":141370018,"url":"https://finnhub.io/api/news?id=059db278a5816d8a3090601824208a14b78b68eed829ec97b66edee7c3671c73","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.","category":"company","datetime":1788278520,"headline":"Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?"}, {"id":141363799,"url":"https://finnhub.io/api/news?id=333be4e944228107f46e82eb4c189a5712c79cf2a54bcdd91358dfdbbae466ef","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"An unusually high volume of out-of-the-money (OTM) put options in Edwards Lifesciences (EW) shows investors are bullish on EW stock over the next three months. Moreover, EW is below analysts' price targets.","category":"company","datetime":1788201002,"headline":"Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock"}, {"id":141363800,"url":"https://finnhub.io/api/news?id=132ff0d47621e88db46c1e729e50927f8e2bf5baad2df7f08e374cd83482bbe8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]","category":"company","datetime":1787938897,"headline":"Edwards Lifesciences (EW): The Medical Device Leader Behind the TAVR Boom"}, {"id":141363801,"url":"https://finnhub.io/api/news?id=2442e1edfe615223b69eb20cffdf7b2349955f48d2cd226ea6fb87f61c0f9bbc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","category":"company","datetime":1787848214,"headline":"Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?"}, {"id":141331543,"url":"https://finnhub.io/api/news?id=5ec2d4c75b529299477c3b76fd4b9480a3d4fae681248ea808c3d10437c3ab15","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_1.jpg?width=2048&height=1536","source":"Benzinga","related":"EW","summary":"Disclosed in a recent SEC filing on August 26, Chopra, CVP at Edwards Lifesciences (NYSE:EW), made a noteworthy transaction involving the exercise of company stock options.\nWhat Happened: The latest Form 4 filing on","category":"company","datetime":1787828534,"headline":"Insider Move: Daveen Chopra Exercises Options, Realizing $551K At Edwards Lifesciences"}, {"id":141363802,"url":"https://finnhub.io/api/news?id=68028d659d2abf6b0bc009ee2e138ce5f9690d34020cbc1d8cf904591ff5838d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"EW","summary":"Medtronic's Q1 results may reflect strong growth across Cardiovascular, Neuroscience and Diabetes, but earnings beat signals remain mixed.","category":"company","datetime":1787755980,"headline":"MDT's Q1 Earnings on Deck: How Should You Play the Stock Now?"}
data_source finnhub_news_keyword_model
article_count 5
negative_hits 0
positive_hits 2
recomputed_at_score true
sentiment_score_raw 1
source_article_count 23
discarded_article_count 18
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 2.7 5/110 54% 2.7
資金流 9.2 20/110 46% 9.2
市場環境 10.2 15/110 68% 10.2
催化劑 2 20/110 10% 2
風險管理 6.8 10/110 68% 6.8
技術信號 14.8 30/110 49.33% 14.8
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 7/50
ret_5d -0.0286
max_score 50
max_total 50
raw_total 7
vcp_bonus 0
vol_ratio 1.2018
ret_points 0
vol_points 4
range_ratio 0.7551
volat_points 0
day_range_pct 0.0174
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 3
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.6

details

atrPct 2.5328
turnoverUsdM 331.6821
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.EW
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 81.3872

strength_details

ma_score 1
atr_score 2
rsi_score 2.5
macd_score 1
volume_score 2
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 5.1
take_profit_price 90.2682
target_multiplier 1.9
technical_strength 1.65
take_profit_percent 5.3
positionPoints 1.6
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 5.0657
diversificationPoints 2

Calculation audit log

基本面分析總分: 2.7/5分
資金流分析總分: 9.2/20分
市場環境分析總分: 10.2/15分
催化劑分析: 2/20分
風險管理總分: 6.8/10分
技術信號分析總分: 14.8/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 78.57
atr
atr 2.1714
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.53
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value -84.03
cmf
rule Cursor_18.24 CMF bands
level 派發
score 2
value -0.1328
kdj
d 55.73
j 40.49
k 50.65
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 弱流入
score 4
value 42.96
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 10
trend 強流入
value -14757418
recentSlope 1153968.2
previousSlope -86720
rsi
value 37.61
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 84.4824
position SAR喺價下
distancePct 1.46
previousTrend 上升
ma50
value 88.3498
macd
macd -0.6855
trend 看跌
signal -0.61
histogram -0.0755
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 88.0874
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.18
score 6
avgVolume 3273756
currentVolume 3868915
derived
ma20 88.1455
ma50 88.3498
prevClose 86.82
avgVolume10 3808031
avgVolume20 3273756
changePercent -1.26
avgVolumeForScore 3273756
ma_cross
ma20 88.1455
ma50 88.3498
rule Cursor_18.24 MA20/MA50 cross
cross 下穿
score 2
prevMa20 88.398
prevMa50 88.3806
spreadPct 0.23
isVolumeBreakout false
bollinger
lower 84.1958
upper 92.0952
position 中間
rsi_short
value 11.5
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.18

Raw calculation JSON

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.5328356467980875,
        "turnoverUsdM": 331.68208295,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.EW",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 81.3872,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.1,
      "take_profit_price": 90.2682,
      "target_multiplier": 1.9,
      "technical_strength": 1.65,
      "take_profit_percent": 5.3
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.065671293596175,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 56.7,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 49.7,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 88.1455,
    "ma50": 88.3498,
    "close": 85.73,
    "prevClose": 86.82,
    "avgVolume20": 3273756,
    "volumeRatio": 1.18,
    "changePercent": -1.26
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": -0.028555240793201042,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 1.2018194436447756,
      "ret_points": 0,
      "vol_points": 4,
      "range_ratio": 0.7550860236354742,
      "volat_points": 0,
      "day_range_pct": 0.017380146973055045,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 56.7,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.7,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 54,
        "contribution": 2.7
      },
      {
        "raw": 9.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 46,
        "contribution": 9.2
      },
      {
        "raw": 10.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 68,
        "contribution": 10.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 68,
        "contribution": 6.8
      },
      {
        "raw": 14.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 49.33,
        "contribution": 14.8
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 49.7,
    "details": [
      "基本面分析總分: 2.7/5分",
      "資金流分析總分: 9.2/20分",
      "市場環境分析總分: 10.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.8/10分",
      "技術信號分析總分: 14.8/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.7,
      "資金流": 9.2,
      "市場環境": 10.2,
      "情緒分析": 4,
      "技術信號": 14.8,
      "風險管理": 6.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 5,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 331.68208295,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.EW",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 14.21
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 719.7049948000001,
                "ma50": 711.88239742,
                "name": "QQQ",
                "close": 741.099976,
                "points": 2
              },
              "spy": {
                "ma20": 765.3379966,
                "ma50": 761.1531977799998,
                "name": "SPY",
                "close": 767.17999,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.5328356467980875,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 5,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 1
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142266550,
                "url": "https://finnhub.io/api/news?id=da0f8c9693d571ce918d448e54f2a4e1f344477545ea3925d87467465be4b61c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences recently outlined its structural heart growth plan, emphasizing transcatheter valve platforms such as TAVR and TMTT, alongside the impact of updated Medicare coverage that could enable 100–200 additional U.S. centers to perform TAVR procedures. A particularly important takeaway is Edwards’ ambition to build a multibillion-dollar transcatheter mitral and tricuspid business by 2030, anchored by PASCAL, EVOQUE, and Sapien M3 technologies that aim to address complex...",
                "category": "company",
                "datetime": 1789769713,
                "headline": "How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions"
              },
              {
                "id": 142260140,
                "url": "https://finnhub.io/api/news?id=e456714e92954de98b33d6053fadb104ecebefa6f418a514898827cc6f127659",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences has delivered a mixed share price story, with the stock up 18.4% over the past year but still down sharply over a 5 year span. This puts the focus squarely on what investors are paying for its future cash flows. With fresh policy news around its core heart valve franchise and a current share price of US$88.25, the key issue is whether the company’s cash generation can support where the stock trades today. Over 5 years the share price has declined 27.1%, which raises the...",
                "category": "company",
                "datetime": 1789755142,
                "headline": "Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion"
              },
              {
                "id": 142197743,
                "url": "https://finnhub.io/api/news?id=9b56623bc1072bd0de84cf62140ea790418711ad90edb1c273a8b5b42899b3ea",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "EW",
                "summary": "Edwards Lifesciences Corporation (EW) Deutsche Bank 2026 Healthcare Summit September 16, 2026 10:00 AM EDTCompany ParticipantsBernard Zovighian - CEO &...",
                "category": "company",
                "datetime": 1789563698,
                "headline": "Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript"
              },
              {
                "id": 141363799,
                "url": "https://finnhub.io/api/news?id=333be4e944228107f46e82eb4c189a5712c79cf2a54bcdd91358dfdbbae466ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "An unusually high volume of out-of-the-money (OTM) put options in Edwards Lifesciences (EW) shows investors are bullish on EW stock over the next three months. Moreover, EW is below analysts' price targets.",
                "category": "company",
                "datetime": 1788201002,
                "headline": "Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock"
              },
              {
                "id": 141363800,
                "url": "https://finnhub.io/api/news?id=132ff0d47621e88db46c1e729e50927f8e2bf5baad2df7f08e374cd83482bbe8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]",
                "category": "company",
                "datetime": 1787938897,
                "headline": "Edwards Lifesciences (EW): The Medical Device Leader Behind the TAVR Boom"
              }
            ],
            "raw_source": [
              {
                "id": 142266550,
                "url": "https://finnhub.io/api/news?id=da0f8c9693d571ce918d448e54f2a4e1f344477545ea3925d87467465be4b61c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences recently outlined its structural heart growth plan, emphasizing transcatheter valve platforms such as TAVR and TMTT, alongside the impact of updated Medicare coverage that could enable 100–200 additional U.S. centers to perform TAVR procedures. A particularly important takeaway is Edwards’ ambition to build a multibillion-dollar transcatheter mitral and tricuspid business by 2030, anchored by PASCAL, EVOQUE, and Sapien M3 technologies that aim to address complex...",
                "category": "company",
                "datetime": 1789769713,
                "headline": "How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions"
              },
              {
                "id": 142260140,
                "url": "https://finnhub.io/api/news?id=e456714e92954de98b33d6053fadb104ecebefa6f418a514898827cc6f127659",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences has delivered a mixed share price story, with the stock up 18.4% over the past year but still down sharply over a 5 year span. This puts the focus squarely on what investors are paying for its future cash flows. With fresh policy news around its core heart valve franchise and a current share price of US$88.25, the key issue is whether the company’s cash generation can support where the stock trades today. Over 5 years the share price has declined 27.1%, which raises the...",
                "category": "company",
                "datetime": 1789755142,
                "headline": "Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion"
              },
              {
                "id": 142251945,
                "url": "https://finnhub.io/api/news?id=37512db8dc48a1b609e465c892d8209fa7791765c124efa21b1a41a2ce7135c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "The global interventional cardiology devices market is forecast to grow from USD 31.12 billion in 2026 to USD 42.39 billion by 2031, at a 6.4% CAGR. Growth is driven by rising cardiovascular disease, aging populations, demand for minimally invasive procedures, better healthcare access, and advances in stents, imaging and catheter technologies. Plain angioplasty balloons, embolic protection devices, guidewires and hospitals will see strong growth, while Asia Pacific is set to be the fastest-growi",
                "category": "company",
                "datetime": 1789727580,
                "headline": "Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031"
              },
              {
                "id": 142225420,
                "url": "https://finnhub.io/api/news?id=3f481a7df661c8f98de5df77adb029ad06c1cffb737eba375692d975ae4fc193",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences (NYSE:EW) outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE",
                "category": "company",
                "datetime": 1789642943,
                "headline": "Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead"
              },
              {
                "id": 142198959,
                "url": "https://finnhub.io/api/news?id=568783958075196b65740530debea12cb32f6534984a1b55719ef4f7c7471b7c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1789585501,
                "headline": "Explore the top gainers and losers within the S&P500 index in today's session."
              },
              {
                "id": 142197673,
                "url": "https://finnhub.io/api/news?id=30298a7b867fc3d1c8506990163ac5c9a3e40dd91ed64cc86b4796e19106bb06",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Wednesday.",
                "category": "company",
                "datetime": 1789576500,
                "headline": "What's going on in today's session: S&P500 movers"
              },
              {
                "id": 142197743,
                "url": "https://finnhub.io/api/news?id=9b56623bc1072bd0de84cf62140ea790418711ad90edb1c273a8b5b42899b3ea",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "EW",
                "summary": "Edwards Lifesciences Corporation (EW) Deutsche Bank 2026 Healthcare Summit September 16, 2026 10:00 AM EDTCompany ParticipantsBernard Zovighian - CEO &...",
                "category": "company",
                "datetime": 1789563698,
                "headline": "Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript"
              },
              {
                "id": 142163400,
                "url": "https://finnhub.io/api/news?id=712ca2141d14c09265822f1d9ad959df7e8bcf8783050923b13cc6f764bc4616",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 7.57% on an annualized basis producing an average annual return of 16.73%. Currently, Edwards Lifesciences has a market capitalization",
                "category": "company",
                "datetime": 1789410618,
                "headline": "$100 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 142089165,
                "url": "https://finnhub.io/api/news?id=730ee985635cf2cb4174a462055018cf2fb3f8c1a7fa9df3fbe6e9889f37215f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1789153501,
                "headline": "Top S&P500 movers in Friday's session"
              },
              {
                "id": 142087699,
                "url": "https://finnhub.io/api/news?id=d008f77c83c23655aa93afca754d58b5809bf8c51f25fceeb225e41d40e1da58",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session.",
                "category": "company",
                "datetime": 1789144501,
                "headline": "Stay informed with the top movers within the S&P500 index on Friday."
              },
              {
                "id": 142088351,
                "url": "https://finnhub.io/api/news?id=5b13fc1b3e7da5df89780e934cc69daf787479d049e9ace50f6b66fc848fab41",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "The Centers for Medicare and Medicaid Services’ policy update extends Medicare coverage to severe aortic stenosis patients without symptoms, a change that analysts said will especially benefit Edwards Lifesciences.",
                "category": "company",
                "datetime": 1789128882,
                "headline": "CMS expands TAVR Medicare coverage to asymptomatic patients"
              },
              {
                "id": 142087525,
                "url": "https://finnhub.io/api/news?id=e1db2e5e73f465a1830dd146275cae0b8f5ac8ba767db9834b8b45a100a239d4",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "BTIG  analyst Marie Thibault   reiterates Edwards Lifesciences (NYSE:EW) with a Buy and maintains $110 price target.",
                "category": "company",
                "datetime": 1789106253,
                "headline": "BTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target"
              },
              {
                "id": 142066287,
                "url": "https://finnhub.io/api/news?id=23a1bbb562bdd05c03a4889d81973e892c03106cf45f4948eabd82d8e4834812",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "IRVINE, Calif., September 10, 2026--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):",
                "category": "company",
                "datetime": 1789076940,
                "headline": "Edwards Lifesciences Comments on TAVR National Coverage Decision"
              },
              {
                "id": 141951037,
                "url": "https://finnhub.io/api/news?id=da6fa2d576819e8545394b26df1efa3f372cede55f32e64c0297eaa73a0dda31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Despite lagging behind the Dow over the past 12 months, Edwards Lifesciences continues to receive a highly bullish outlook from Wall Street analysts.",
                "category": "company",
                "datetime": 1788859207,
                "headline": "Is Edwards Lifesciences Stock Underperforming the Dow?"
              },
              {
                "id": 141758077,
                "url": "https://finnhub.io/api/news?id=f0abeae7b345fcf63f4ae44fa3cce64a78b15eb65c0eec0d640baaff2b2fd7c4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249179691/image_2249179691.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "EW",
                "summary": "Baron Asset Fund initiated a position in Edwards Lifesciences due to its dominant heart valve market share. Read the full analysis for more details.",
                "category": "company",
                "datetime": 1788750600,
                "headline": "Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound"
              },
              {
                "id": 141437930,
                "url": "https://finnhub.io/api/news?id=363996b5598cdc6cbd4a9ff5b8357ca4a6e2dfb3b9ccf4040974e9945cfc3d7f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535817,
                "headline": "Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141381180,
                "url": "https://finnhub.io/api/news?id=aff4cd1f434fbbb0d65c87f29c8c7560f83d23928031121fd5c2ed58c880051b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "IRVINE, Calif., September 02, 2026--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.",
                "category": "company",
                "datetime": 1788383700,
                "headline": "Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit"
              },
              {
                "id": 141370018,
                "url": "https://finnhub.io/api/news?id=059db278a5816d8a3090601824208a14b78b68eed829ec97b66edee7c3671c73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.",
                "category": "company",
                "datetime": 1788278520,
                "headline": "Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?"
              },
              {
                "id": 141363799,
                "url": "https://finnhub.io/api/news?id=333be4e944228107f46e82eb4c189a5712c79cf2a54bcdd91358dfdbbae466ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "An unusually high volume of out-of-the-money (OTM) put options in Edwards Lifesciences (EW) shows investors are bullish on EW stock over the next three months. Moreover, EW is below analysts' price targets.",
                "category": "company",
                "datetime": 1788201002,
                "headline": "Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock"
              },
              {
                "id": 141363800,
                "url": "https://finnhub.io/api/news?id=132ff0d47621e88db46c1e729e50927f8e2bf5baad2df7f08e374cd83482bbe8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]",
                "category": "company",
                "datetime": 1787938897,
                "headline": "Edwards Lifesciences (EW): The Medical Device Leader Behind the TAVR Boom"
              },
              {
                "id": 141363801,
                "url": "https://finnhub.io/api/news?id=2442e1edfe615223b69eb20cffdf7b2349955f48d2cd226ea6fb87f61c0f9bbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1787848214,
                "headline": "Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?"
              },
              {
                "id": 141331543,
                "url": "https://finnhub.io/api/news?id=5ec2d4c75b529299477c3b76fd4b9480a3d4fae681248ea808c3d10437c3ab15",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Disclosed in a recent SEC filing on August 26, Chopra, CVP at Edwards Lifesciences (NYSE:EW), made a noteworthy transaction involving the exercise of company stock options.\nWhat Happened: The latest Form 4 filing on",
                "category": "company",
                "datetime": 1787828534,
                "headline": "Insider Move: Daveen Chopra Exercises Options, Realizing $551K At Edwards Lifesciences"
              },
              {
                "id": 141363802,
                "url": "https://finnhub.io/api/news?id=68028d659d2abf6b0bc009ee2e138ce5f9690d34020cbc1d8cf904591ff5838d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Medtronic's Q1 results may reflect strong growth across Cardiovascular, Neuroscience and Diabetes, but earnings beat signals remain mixed.",
                "category": "company",
                "datetime": 1787755980,
                "headline": "MDT's Q1 Earnings on Deck: How Should You Play the Stock Now?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 5,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1,
            "source_article_count": 23,
            "discarded_article_count": 18
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 14.8,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.7,
          "macdPoints": 0.8,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.7,
            "vcp_reason": "波幅收縮(11.6%→6.9%);升放量(近10日5日);Ready=N;Confirm=N",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 3045843.2333333334,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 3652139.7,
              "avg_vol_20": 3219214.85,
              "avg_vol_30": 3045843.2333333334,
              "range_pct_10": 0.06870407092033128,
              "range_pct_20": 0.10661378747229674,
              "range_pct_30": 0.11594541000816513,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 5,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.1990570164713117,
              "dist_to_20d_high": 0.07767616998386227,
              "down_shrink_days": 0,
              "breakout_level_20d": 92.95,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5925553319919519
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 1.6,
          "volumeWeight": 2,
          "maCrossPoints": 0.8,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.5328356467980875,
              "turnoverUsdM": 331.68208295,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.EW",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 81.3872,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.1,
            "take_profit_price": 90.2682,
            "target_multiplier": 1.9,
            "technical_strength": 1.65,
            "take_profit_percent": 5.3
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.065671293596175,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 2.1714,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.53
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -84.03
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.1328
    },
    "kdj": {
      "d": 55.73,
      "j": 40.49,
      "k": 50.65,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 42.96
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": -14757418,
      "recentSlope": 1153968.2,
      "previousSlope": -86720
    },
    "rsi": 37.61,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 84.4824,
      "position": "SAR喺價下",
      "distancePct": 1.46,
      "previousTrend": "上升"
    },
    "ma50": 88.3498,
    "macd": {
      "macd": -0.6854911106535013,
      "trend": "看跌",
      "signal": -0.6099943358404627,
      "histogram": -0.07549677481303863
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 88.0874,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.18,
      "score": 6,
      "avgVolume": 3273756,
      "currentVolume": 3868915
    },
    "derived": {
      "ma20": 88.1455,
      "ma50": 88.3498,
      "prevClose": 86.82,
      "avgVolume10": 3808031,
      "avgVolume20": 3273756,
      "changePercent": -1.26,
      "avgVolumeForScore": 3273756
    },
    "ma_cross": {
      "ma20": 88.1455,
      "ma50": 88.3498,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "下穿",
      "score": 2,
      "prevMa20": 88.398,
      "prevMa50": 88.3806,
      "spreadPct": 0.23,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 84.1958,
      "upper": 92.0952,
      "position": "中間"
    },
    "rsi_short": 11.5,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.18
    }
  }
}

Raw metrics JSON

{
  "close": 85.73,
  "volume": 3868915,
  "changePercent": -1.26
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank provides research support only and does not provide financial advice or buy/sell recommendations.